NEW YORK – Sera Prognostics this week reported third quarter revenues of $87,000 compared to $23,000 a year ago. The Salt Lake City-based company's Q3 R&D expenses jumped 56 percent to $4.2 million from $2.7 million a year ago due to increased laboratory operations and clinical study costs related to its PreTRM blood-based biomarker test for preterm birth risk prediction. Sera reported a Q3 net loss of $10.7 million, or $.35 per share, compared to a net loss of $9.9 million, or $.39 per share, a year ago. The company finished the quarter with $38.8 million in cash and cash equivalents and $50.0 million in marketable securities.
Aspira Women’s Health said this week that its third quarter revenues were $2.1 million, up 24 percent from $1.7 million in Q3 2021. The company performed 5,524 of its Ova1Plus ovarian cancer tests during the quarter, up 29 percent from 4,281 tests performed in Q3 2021. The Austin, Texas-based diagnostics company had a net loss of $4.6 million, or $.04 per share, in Q3 compared to a net loss of $9.7 million, or $.09 per share, in the year-ago period. It ended the quarter with $20.6 million in cash and cash equivalents and $250,000 in restricted cash.
Immunovia this week said that its net sales for the three months ended Sept. 30 fell 5 percent year over year to SEK 358,000 ($33,409) from SEK 377,000 during the year-ago period. Its net loss for the recently completed quarter was SEK 23 million, or SEK 1.01, compared to a net loss of SEK 36 million, or SEK 1.60, a year ago. The Swedish developer of blood-based diagnostics ended the quarter with SEK 159 million in cash and cash equivalents.
ProPhase Labs this week said that its third quarter revenues grew to $24.2 million from $9.5 million a year ago. It had a net income of $969,000, or $.06 per share, for the recently completed quarter compared to a net loss of $4.0 million, or $.26 per share, a year ago. The company exited the quarter with $22.8 million in cash and cash equivalents and $3.7 million in marketable debt securities.
Prenetics this week reported $79.7 million in revenues for the third quarter, up 7 percent from $74.7 million during the same period last year. The Hong Kong-based diagnostics and genetic testing company had a net loss of $14.9 million, or $.21 per share, in Q3 compared to a net loss of $80.4 million, or $2.65 per share, in the year-ago quarter. The firm used 70.4 million weighted average common shares to calculate its Q3 net loss this year versus 30.4 million shares a year ago. It ended the quarter with $144.7 million in cash and cash equivalents. Prenetics raised its full-year 2022 revenue guidance to a range of $270 million to $280 million. https://www.marketwatch.com/press-release/prenetics-announces-
Devyser Diagnostics said this week its net sales grew 28 percent to SEK 31.2 million ($2.9 million) for the third quarter from SEK 24.3 million a year ago. The firm reported a net loss of SEK 8.8 million, or SEK .55 per share, for the three months ended Sept. 30 compared to a loss of SEK 3.6 million, or SEK .32 a year ago. It finished the quarter with SEK 382.2 million in cash and cash equivalents. The firm reported it also gained certification in August for its quality management system and fetal diagnostics product under Europe's In Vitro Diagnostic Regulation, which took effect in May. The firm also said it plans to establish a CLIA-certified laboratory in Atlanta and to start the lab's operations by the second quarter of 2023, which would let the company offer testing services directly to US customers.